antibody

Rabbit anti SOCS-3 antibody

MBS462133

0.1 mg

250 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, ELISA, immunohistochemistry

Antibody

Rabbit anti SOCS-3 antibody

SOCS3

Rabbit anti-SOCS-3; Suppressor of Cytokine Signaling 3 (SOCS3); CIS3

suppressor of cytokine signaling 3; Suppressor of cytokine signaling 3; suppressor of cytokine signaling 3; CIS-3; STAT-induced STAT inhibitor 3; cytokine-induced SH2 protein 3; cytokine-inducible SH2 protein 3; suppressor of cytokine signaling 3; Cytokine-inducible SH2 protein 3; CIS-3; STAT-induced STAT inhibitor 3

SOCS3

SOCS3; SOCS3; CIS3; SSI3; ATOD4; Cish3; SSI-3; SOCS-3; MGC71791; CIS3; SSI3

SOCS3_HUMAN

Rabbit

Human, Mouse, Rat

This antibody recognizes ~27 kDa of SOCS-3 protein from human and mouse origins. The other species are not tested.

The Rabbit IgG is purified by Epitope Affinity Purification.

This affinity purified antibody is supplied in sterile Phosphatebuffered saline (pH7.2) containing antibody stabilizer.

Size: 100 ug/200 ul

The antibodies are stable for 12 months from date of receipt when stored at -20 degree C to -70 degree C. The antibodies can be stored at 2 degree C-8 degree C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.

ELISA, Western Blot, Immunohistochemistry

Western Blot: 0.1-1 ug/ml. ELISA: 0.01-0.1 ug/ml. Immunoprecipitation: 2-5 ug/ml. Immunohistochemistry: 0.5-2 ug/ml

Antigen Preparation: A synthetic peptide corresponding to the C-terminus of SOCS-3 protein from human, mouse and rat origins.

Positive Control: Mouse liver lysate

Cytokines induce a variety of biological responses by binding to specific cell surface receptors and activating cytoplasmic signal transduction pathways which are suppressed by other transcriptional factors. Proteins that mediate these signals from the cell surface to the nucleus include JAKs and STATs, while SOCS (Suppressor of cytokine signaling) proteins inhibit those signaling. The SOCS family comprises at least 8 members, SOCS1 to SOCS7 and CIS (cytokine inducible SH2 containing protein). Structurally, the SOCS proteins are composed of an N terminal region of variable length and amino acid composition, a central SH2 domain, and a previously unrecognized C terminal motif named the SOCS box. SOCS 3 regulates fetal liver hematopoiesis. It is also involved in a broad spectrum of cytokines, such as IL-2, IL-3, IL-4, IL-6, Epo, Prolactin, and GH.

Selinda J. Orr, et al. SOCS3 Targets Siglec 7 for Proteasomal Degradation and Blocks Siglec 7-mediated Responses. J. Biol. Chem., Feb 2007; 282: 3418 - 3422.

45439352

NP_003946.3

NM_003955.3

O14543

27 kDa

ATF-2 Transcription Factor Network Pathway (138006); Adaptive Immunity Signaling Pathway (366160); Adipocytokine Signaling Pathway (83093); Adipocytokine Signaling Pathway (505); Adipogenesis Pathway (198832); Antigen Processing: Ubiquitination Proteasome Degradation Pathway (366162); Class I MHC Mediated Antigen Processing Presentation Pathway (366161); Cytokine Signaling In Immune System Pathway (366171); EGFR1 Signaling Pathway (198782); EPO Signaling Pathway (138051)

This gene encodes a member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling (SOCS), family. SSI family members are cytokine-inducible negative regulators of cytokine signaling. The expression of this gene is induced by various cytokines, including IL6, IL10, and interferon (IFN)-gamma. The protein encoded by this gene can bind to JAK2 kinase, and inhibit the activity of JAK2 kinase. Studies of the mouse counterpart of this gene suggested the roles of this gene in the negative regulation of fetal liver hematopoiesis, and placental development. [provided by RefSeq]

Function: SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo. By similarity. Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST. By similarity. Ref.9. Pathway: Protein modification; protein ubiquitination. Subunit structure: Interacts with multiple activated proteins of the tyrosine kinase signaling pathway including IGF1 receptor, insulin receptor and JAK2. Binding to JAK2 is mediated through the KIR and SH2 domains to a phosphorylated tyrosine residue within the JAK2 JH1 domain. Binds specific activated tyrosine residues of the leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with CSNK1E stabilizes SOCS3 protein. Component of the probable ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with CUL5, RNF7, TCEB1 and TCEB2. Interacts with CUL2. Ref.5 Ref.6 Ref.7 Ref.8 Ref.9. Tissue specificity: Widely expressed with high expression in heart, placenta, skeletal muscle, peripheral blood leukocytes, fetal and adult lung, and fetal liver and kidney. Lower levels in thymus. Domain: The ESS and SH2 domains are required for JAK phosphotyrosine binding. Further interaction with the KIR domain is necessary for signal and kinase inhibition.The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes. Post-translational modification: Phosphorylated on tyrosine residues after stimulation by the cytokines, IL-2, EPO or IGF1. Involvement in disease: Note=There is some evidence that SOCS3 may be a susceptibility gene for atopic dermatitis linked to 17q25. SOCS3 messenger RNA is significantly more highly expressed in skin from patients with atopic dermatitis than in skin from healthy controls. Furthermore, a genetic association between atopic dermatitis and a haplotype in the SOCS3 gene has been found in two independent groups of patients. Pharmaceutical use: Could be used as a possible therapeutic agent for treating rheumatoid arthritis. Sequence similarities: Contains 1 SH2 domain.Contains 1 SOCS box domain.

0.1 mg

250 USD